Phaseline

Companies › Shenzhen Majory Biotechnology

Shenzhen Majory Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MR001
Bispecific antibody
–Phase 1Pancreatic Ductal Adenocarcinoma (PDAC); Triple-Negative Breast Cancer (TNBC)Jun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07235202MR001Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)OncologyJun 2028
NCT07208149MR001Phase 1Triple-Negative Breast Cancer (TNBC)OncologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.